The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The Cystic Fibrosis Market has been comprehensively analyzed in IMARC’s new report titled “Cystic Fibrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast”. Cystic fibrosis is an inherited disorder that adversely affects the lungs, digestive system, pancreas, etc. It influences the cells that produce mucus, sweat, and digestive juices. People suffering from cystic fibrosis have defective genes that make digestive secretions thick and sticky and plug up ducts, passageways, and tubes, especially in the lungs and pancreas. The individuals who are not diagnosed until adulthood have milder diseases and experience symptoms like recurring incidences of an inflamed pancreas (pancreatitis), infertility, and pneumonia. Doctors may give drugs to open airways, thin mucus, prevent infections, and help the body get enough nutrients to fulfill its requirements. The other probable treatment options for cystic fibrosis are airway clearance techniques, vascular access devices, CFTCR modulators, surgical procedures, physical therapies, etc.
The rising prevalence of genomic mutations coupled with the increasing demand for effective medications that can treat such conditions is primarily driving the cystic fibrosis market. In addition to this, the shifting preferences of patients from intravenous therapy towards oral treatment options since they are cost-effective and less time-consuming are also propelling the market growth. Moreover, the emerging popularity of lentivirus gene therapy over conventional retroviral gene delivery systems owing to its several associated benefits, such as the ability to provide long-term and stable gene expression and to infect non-dividing cells, is also creating a positive outlook for the market. Besides this, the widespread adoption of cystic fibrosis transmembrane conductance (CFTR) modulators as a treatment alternative is bolstering the market growth. CFTRs are intended to regulate the flow of chloride and water through the cell linings of the lungs and rectify the malfunctioning protein in the body. Additionally, the ongoing development of personalized drug therapy, molecular prosthetics, and innovative drugs with improved efficacy is expected to drive the cystic fibrosis market in the coming years.
IMARC Group’s new report "Cystic Fibrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Cystic Fibrosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides an in-depth understanding of current and future landscape of the Cystic Fibrosis market. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Cystic Fibrosis across the seven major markets. According to the report the United States has the largest patient pool for Cystic Fibrosis and also represents the largest market for Cystic Fibrosis treatment. Furthermore, the current Cystic Fibrosis treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Cystic Fibrosis market in any manner.
Time Period of the Study
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current Cystic Fibrosis marketed drugs and late-stage pipeline drugs.
In-Market Cystic Fibrosis Drugs
Late-Stage Pipeline Cystic Fibrosis Drugs
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
Pregnancy Detection Kits Market by Product (Home Pregnancy Tests (HPT), Digital Devices, and Others), Test Type (Urine Test for HCG, Blood Test for HCG, and Others), End User (Household, Gynecology Clinics, Hospitals), and Region 2023-2028
Swine Healthcare Market by Product (Diagnostic Tests, Therapeutics), Disease (Exudative Dermatitis, Coccidiosis, Respiratory Diseases, Swine Dysentery, Porcine Parvovirus, and Others), Route of Administration (Injectable, Oral), Distribution Channel (Veterinary Hospitals, Retail Pharmacy, Online Pharmacy), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at